<?xml version="1.0" encoding="UTF-8" standalone="no" ?>
<rss version="2.0">
  <channel>
    <title>Hak, E.</title>
    <link>http://repub.eur.nl/res/aut/9540/</link>
    <description>List of Publications</description>
    <language>en</language>
    <image>
      <url>http://repub.eur.nl/static-eur/img/logo.png</url>
      <title>RePub, Erasmus University Rotterdam</title>
      <link>http://repub.eur.nl</link>
    </image>
    <item>
      <title>Evaluation of impermeable covers for bedding in patients with allergic rhinitis (Article)</title>
      <link>http://repub.eur.nl/res/pub/8457/</link>
      <pubDate>2003-01-01T00:00:00Z</pubDate>
      <description>BACKGROUND: Encasing bedding in impermeable covers reduces exposure to
      house-dust mites, but the clinical benefit of this intervention as part of
      mite-avoidance measures for patients with allergic rhinitis is not known.
      We performed a multicenter, randomized, placebo-controlled trial of one
      year of use of impermeable bedding covers in the bedrooms of patients with
      rhinitis who were sensitized to house-dust mites to determine the effects
      on the signs and symptoms of disease. METHODS: Three participating
      university medical centers enrolled 279 patients with allergic rhinitis
      who were randomly assigned to receive impermeable or non-impermeable
      (control) covers for their mattress, pillow, and duvet or blanket. At the
      start of the study, all participants received information on general
      allergen-avoidance measures. The severity of rhinitis was measured on a
      rhinitis-specific visual-analogue scale and by means of a daily symptom
      score and nasal allergen provocation testing. We also measured the
      concentrations of Dermatophagoides pteronyssinus (Der p1) and D. farinae
      (Der f1) in dust from patients' mattresses, bedroom floors, and
      living-room floors at base line and after 12 months as a measure of the
      efficacy of the intervention. RESULTS: A total of 232 patients completed
      the study. There was a significant reduction in Der p1 and Der f1
      concentrations in the mattresses of the impermeable-cover group, whereas
      there was no significant reduction in the control group. However, there
      was no significant effect on the clinical outcome measures. Analyses of
      subgroups defined according to age, level of exposure, type and severity
      of sensitization, or characteristics of the patient's home had similar
      results. CONCLUSIONS: Mite-proof bedding covers, as part of a structured
      allergy-control program, reduced the level of exposure to mite allergens.
      Despite the success of the intervention, this single avoidance measure did
      not lead to a significant improvement of clinical symptoms in patients
      with allergic rhinitis.</description>
    </item>
  </channel>
</rss>